Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 2/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11750036 | 0.79 | SLC6A4 (0.60) | SLC6A4HTR1ASLC6A9SCN4ACHRNB2 | |
| SCHEMBL18960366 | 0.79 | NOS2 (0.62) | SLC6A4HTR1ASLC6A9SCN4ACHRNB2 | |
| SCHEMBL7049684 | 0.77 | SLC6A4 (0.66) | SLC6A4HTR1ASLC6A9SCN4ACHRNB2 | |
| SCHEMBL7051333 | 0.76 | SLC6A4 (1.00) | SLC6A4NOS2 | |
| SCHEMBL11750939 | 0.75 | SLC6A4 (0.56) | SLC6A4HTR1ASLC6A9SCN4APPARG | |
| SCHEMBL11750508 | 0.75 | SLC6A4 (0.56) | SLC6A4HTR1ASLC6A9SCN4ACHRNB2 | |
| SCHEMBL18960367 | 0.74 | SLC6A4 (0.51) | SLC6A4HTR1ASLC6A9PPARGPPARA | |
| SCHEMBL17278127 | 0.73 | SLC7A5 (0.68) | SLC6A4HTR1ASLC6A9NOS2 | |
| SCHEMBL11360054 | 0.73 | SLC6A4 (0.57) | SLC6A4SLC6A9SCN4ACHRNB2CHRNA4 | |
| SCHEMBL10913184 | 0.73 | SLC6A4 (0.68) | SLC6A4SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| WO-2016016421-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | ALOX5, ALOX15, ALOX12 | SLC6A4 2954/4885HTR1A 407/4885SLC6A9 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.